The in vitro activity of ceftaroline and ceftobiprole was assessed against 77 Gram-positive bacterial isolates recovered from patients diagnosed with infective endocarditis (IE). Our data confirm that these drugs are highly in vitro active against the most common agents of IE including methicillin-resistant Staphylococcus aureus, methicillin-resistant coagulase-negative staphylococci, and Streptococcus spp., with no significant differences between them. Also, ceftaroline and ceftobiprole have demonstrated a good activity against Enterococcus faecalis (MIC₉₀ 0.75 μg/mL and 0.5 μg/mL, respectively). The spectrum of these drugs together with the in vitro and in vivo data on them related with IE published in the scientific literature places them as potential options for the initial management of this disease.

针对从诊断为感染性心内膜炎 (IE) 的患者中回收的 77 株革兰氏阳性细菌分离株，评估了头孢洛林和头孢比普罗的体外活性。我们的数据证实，这些药物对最常见的 IE 病原体具有高度体外活性，包括耐甲氧西林金黄色葡萄球菌、耐甲氧西林凝固酶阴性葡萄球菌和链球菌属，并且它们之间没有显着差异。此外，头孢洛林和头孢比普罗已表现出良好的抗粪肠球菌活性（MIC ₉₀分别为 0.75 μg/mL 和 0.5 μg/mL）。这些药物的谱以及科学文献中发表的与 IE 相关的体外和体内数据使它们成为该疾病初始管理的潜在选择。